Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs InMode Ltd (INMD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs InMode Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while InMode Ltd trades at $15.7 (market cap $878.88M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 45.4× InMode Ltd's market cap, and InMode Ltd is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | INMD | |
|---|---|---|
Market Cap | $39.89B | $878.88M |
Sector | Health | Technology |
52-Week High | $491.22 | $16.62 |
52-Week Low | $278.09 | $12.76 |
Enterprise Value | $38.15B | $346.55M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
INMD trades at $15.28, up 1.8% on the day, with a bullish technical signal from moving averages and oscillators. The company reported a Q1 2026 earnings miss but maintains strong profitability with a 23.27% net income margin. Recent news includes an unsolicited acquisition proposal from Steel Partners at $16.75 per share, alongside ongoing securities fraud investigations announced in early July 2026.
The stock presents a mixed outlook; the acquisition offer and solid fundamentals suggest upside near the $16.50 consensus target, but legal scrutiny and earnings volatility pose significant risks. Investor sentiment is divided, with analysts evenly split between Buy and Hold ratings, reflecting uncertainty around the company's near-term trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →
